Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Carbapenem-Based Antibiotics Market Evolve in Terms of Growth and Size by 2029?

Over the recent years, the market size for carbapenem-based antibiotics has seen a constant growth. The market is projected to escalate from $4.6 billion in 2024 to $4.78 billion in 2025, experiencing a compound annual growth rate (CAGR) of 3.8%. The upward trend during the historic period is due to factors such as epidemics and pandemics, an increase in chronic diseases, advancements in healthcare infrastructure, fast-paced urbanization, and health-related exigencies due to natural calamities.

The market for carbapenem-based antibiotics is predicted to experience significant growth in the ensuing years. The market size is anticipated to reach $5.97 billion in 2029, with a compound annual growth rate (CAGR) of 5.7%. This forthcoming growth can be linked to factors such as the rising occurrence of infections acquired in hospitals, the emergence of multi-drug resistant strains, an increasing elderly populace, the growth in surgical procedures, the spread of infectious diseases, and changing demographics. During the forecast period, a few notable trends will emerge including an emphasis on supply chain stability and security, development of alternative treatments, a shift to outpatient settings, increased cognizance of antimicrobial stewardship, and the application of precision medicine approaches.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12035&type=smp

What factors are expected to fuel Carbapenem-Based Antibiotics market growth in the coming years?

As bacterial infections proliferate, it is predicted that demand for carbapenem-based antibiotics, which treat severe, multi-drug resistant infections caused by both gram-positive and gram-negative bacteria, will rise commensurately. Bacteria, microscopic entities with the potential to infiltrate the human body and induce various maladies and symptoms, are the source of these infections. For instance, the Centers for Disease Control and Prevention, a U.S government agency, reported in July 2024 that during 2023, 78% of all bacterial infections within its research boundaries were detected via CIDTs, with CIDTs exclusively identifying 46% of these. Consequently, the escalating occurrence of bacterial infections is fueling the expansion of the carbapenem-based antibiotics market.

What Are The Key Findings From The Segmentation Analysis Of The Carbapenem-Based Antibiotics Market?

The carbapenem-based antibiotics market covered in this report is segmented –

1) By Type: Meropenem, Imipenem, Doripenem, Tebipenem, Other Types

2) By Indication: Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin And Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Meropenem: Meropenem Injection, Meropenem and Vaborbactam Combination, Meropenem for Pediatric Use

2) By Imipenem: Imipenem and Cilastatin Combination, Imipenem and Relebactam Combination, Imipenem Monotherapy

3) By Doripenem: Doripenem Injection, Doripenem for Complicated Infections

4) By Tebipenem: Tebipenem for Oral Administration, Tebipenem Pediatric Formulations, Tebipenem for Resistant Infections

5) By Other Types: Ertapenem, Panipenem, Faropenem, Combinations with Beta-Lactamase Inhibitors

Which Trends Are Expected To Shape The Future Of The Carbapenem-Based Antibiotics Market?

The rising trend in the carbapenem-based antibiotics market is the innovation of products. Competing companies are producing innovative products to maintain their market presence. The UK National Health Service, a governmental department, pioneered a subscription scheme for antibiotics with the pharmaceutical industry in August 2024 to combat antimicrobial resistance (AMR). The scheme, announced on August 12, 2024, enables pharmaceutical companies to receive a fixed annual payment—amounting to up to £20 million per drug—irrespective of prescription quantity, thereby eliminating the encouragement for excessive use. It is estimated that the scheme, aiming to stimulate the creation of new antibiotics by guaranteeing financial viability for pharmaceutical companies, will be worth around £1.9 billion over a span of 16 years. This move comes after a successful test phase, aligning with the UK’s larger agenda to combat AMR, which if overlooked might result in a significant number of fatalities globally by 2050. In this endeavour, the NHS intends to give preference to products that target critical pathogens as recognized by the World Health Organization, thereby reaffirming its responsible use of antibiotics, while promoting innovation in antibiotic development.

What Are The Most Active Companies In The Carbapenem-Based Antibiotics Market Today?

Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/carbapenem-based-antibiotics-global-market-report

Which Regional Markets Are Attracting The Most Investment In Carbapenem-Based Antibiotics?

North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12035&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model